NanoViricides, Inc.

331 articles with NanoViricides, Inc.

• NanoViricides Provides Additional Details on Its Rapid Monkeypox Drug Strategy

  8/9/2022

  NanoViricides, Inc. provides further details on its rapid drug development strategy for Monkeypox virus.

• NanoViricides Reports That It Has Begun Drug Development to Combat Monkeypox Virus

  8/4/2022

  NanoViricides, Inc., a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, reports that it has begun drug development to combat the monkeypox virus.

• NanoViricides Has Filed Quarterly Report for Period Ending March 31, 2022 - Has Sufficient Cash, NV-CoV-2 Coronavirus Drug Candidate Progressing Further for Clinical Trials Application

  5/17/2022

  NanoViricides, Inc. a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, has filed the quarterly report for third quarter of its 2022 fiscal year with the Securities and Exchange Commission.

• 

  Latest Count has Mysterious Pediatric Hepatitis at 450 Cases Worldwide

  5/16/2022

  The European Center for Disease Prevention and Control said the number of unusual pediatric hepatitis cases has reached 450, double the number reported two weeks ago.

• NanoViricides Reports that It Has Begun Drug Development to Combat Recent Cases of Severe Pediatric Hepatitis

  5/16/2022

  NanoViricides, Inc. a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform reports that it has begun drug development to combat recent cases of severe pediatric hepatitis.

• NanoViricides Provides Update On NV-CoV-2 Coronavirus Drug Candidate Program

  4/25/2022

  NanoViricides, Inc. a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform is providing an update on its clinical-trial ready Coronavirus Oral and Injectable Drug Programs.

• NanoViricides Has Filed Quarterly Report for Period Ending December 31, 2021

  2/15/2022

  NanoViricides, Inc has filed the quarterly report for second quarter of its 2022 fiscal year with the Securities and Exchange Commission.

• NanoViricides Has Filed Quarterly Report for Period Ending September 30, 2021 - Has Sufficient Cash, Coronavirus Drug Candidate Moving Towards Clinical Trials

  11/16/2021

  NanoViricides, Inc. has filed its quarterly report for its first quarter of financial year 2022 with the Securities and Exchange Commission.

• NanoViricides Completes Oral Gummies and Lung Inhalation Formulations Development for its Non-Mutagenic, Safe, Broad-Spectrum COVID-19 Clinical Drug Candidate, NV-CoV-2

  11/15/2021

  NanoViricides, Inc. announced today that it has developed oral gummies formulations of its Pan-Coronavirus COVID-19 Drug Candidate NV-CoV-2 to benefit non-hospitalized patients.

• NanoViricides, Inc. Has Filed its Annual Report: Coronavirus Drug Program Rapidly Moving Towards Clinical Stage

  10/13/2021

  NanoViricides, Inc., reports that it has filed its Annual Report on Form 10-K for the fiscal year ending June 30, 2021 with the Securities and Exchange Commission on Tuesday, October 12, 2021.

• NanoViricides Announces COVID-19 Clinical Drug Candidate NV-CoV-2 was Effective Against SARS-CoV-2, Further Demonstrating Its Broad-Spectrum Pan-Coronavirus Activity

  10/11/2021

  NanoViricides, Inc. announced that its Pan-Coronavirus COVID-19 Drug Candidate NV-CoV-2 was found to be effective against SARS-CoV-2 in a standard cell culture pseudovirion assay, demonstrating that the drug indeed has broad-spectrum pan-coronavirus activity.

• NanoViricides Completes Licensing for Coronavirus Field which Includes Current COVID-19 Drug Development

  9/14/2021

  NanoViricides, Inc., a global leader in nanomedicines against viruses, announced that it has completed the process of licensing the human Coronavirus field for drug development and commercialization from TheraCour Pharma, Inc.

• NanoViricides Has Filed Quarterly Report for Period Ending March 31, 2021 - Has Sufficient Cash, Coronavirus Drug Candidate Moving Towards IND

  5/17/2021

  NanoViricides, Inc. a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, has filed its quarterly report for its third quarter of financial year 2021 with the Securities and Exchange Commission.

• NanoViricides, Inc. Pan-coronavirus COVID-19 Drug Candidates Are Highly Effective in Pre-clinical Animal Studies in Support of FDA Pre-IND Application

  3/9/2021

  NanoViricides, Inc., a leader in the development of highly effective antiviral therapies based on a novel nanomedicines technology, reported on the strong effectiveness of its two COVID-19 clinical drug candidates in an animal model of coronavirus infection.

• NanoViricides, Inc. Pan-coronavirus Clinical Drug Candidates for the Treatment of COVID-19 Are Highly Effective in Pre-clinical Cell Culture Studies Performed in Preparation of FDA Pre-IND Application

  3/2/2021

  NanoViricides, Inc. a leader in the development of highly effective antiviral therapies based on a novel nanomedicine technology platform, reported on the strong pan-coronavirus effectiveness of its two COVID-19 clinical drug candidates for which the Company is preparing a pre-IND application.

• NanoViricides Has Filed Quarterly Report for Period Ending December 31, 2020 - Has Sufficient Cash, Coronavirus Drug Candidate Safe in GLP Safety Toxicology Moving Towards IND

  2/17/2021

  NanoViricides, Inc. a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, has filed its quarterly report for its second quarter of financial year 2021 with the Securities and Exchange Commission.

• NanoViricides’s Broad-Spectrum Antiviral Drug Candidate for the Treatment of COVID-19 Infections was Well Tolerated in GLP and non-GLP Animal Safety Studies

  2/8/2021

  NanoViricides, Inc. has announced today that its broad-spectrum anti-coronavirus drug candidate for the treatment of COVID-19 infections was well tolerated in safety pharmacology studies required for progressing to human clinical trials.

• Broad-Spectrum Direct Antiviral Nanomedicine Should Remain Effective Against COVID-19 Virus Variants, Says NanoViricides, Inc.’s President, Dr. Anil Diwan

  1/27/2021

  NanoViricides, Inc. a global leader in the development of highly effective broad-spectrum antiviral therapies based on a novel nanomedicines platform, discusses the current developments in the COVID-19 pandemic and the Company's exciting accomplishments related to it.

• NanoViricides Strengthens its Board of Directors with Addition of Industry Veteran Brian Zucker, CPA

  11/19/2020

  NanoViricides, Inc., a leader in developing novel nanomedicines to treat viral diseases, announced that Mr. Brian Zucker, CPA, has joined the Company's Board of Directors, effective November 13, 2020, as an independent director.

• NanoViricides Has Filed Quarterly Report for Period Ending September 30, 2020 - Has Sufficient Cash, Coronavirus Drug Development Progress

  11/17/2020

  NanoViricides, Inc. a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, has filed its quarterly report for its first quarter of financial year 2021 with the Securities and Exchange Commission.